Biotech

All Articles

Lilly blog posts even more positive information on its once a week insulin prospect

.On the heels of an FDA denial for its own chief rival Novo Nordisk, Eli Lilly is actually picking u...

IN 8bio halts phase 2 test, lays off half of workforce

.Simply a handful of months after dosing the initial patient in a period 2 test for recently identif...

Lilly, Haya ink $1B biobuck excessive weight treaty to browse dark genome

.Eli Lilly's look for weight problems aim ats has led it to the dark genome. The Big Pharma has come...

ArsenalBio increases $325M, pivots out of past lead possession

.Arsenal Biosciences is actually going on up. The cell therapy provider has added $325 thousand in a...

Lilly- backed weight-loss biotech reports IPO

.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has submitted ...

Aelis' cannabis use medication flunks phase 2b, steering Indivior to reconsider $100M choice

.Aelis Farma's chances of safeguarding a quick, favorable decision on a $100 million choice payment ...

ProKidney standstills period 3 trial certainly not required for cell treatment confirmation

.ProKidney has ceased some of a pair of phase 3 trials for its tissue therapy for renal ailment afte...

Vaxcyte climbs on 'remarkable' 31-valent PCV gain against Pfizer

.Vaxcyte unveiled what experts called "magnificent" phase 1/2 data for its own 31-valent pneumococca...

Recursion's brain condition test presents insufficient documentation of effectiveness

.Recursion has discovered by means of a very early test of its own tech-enabled strategy to medicine...

Acepodia, Pfizer click on together for chemistry-based tissue therapy

.Contact it an instance of really good chemistry: Acepodia, a biotech based upon Nobel Champion scie...